Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.

Abbisko Cayman Limited
和譽開曼有限責任公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT
ABBISKO THERAPEUTICS PRESENTS A NOVEL JOINT MODELING FRAMEWORK FOR ABSK-011 (IRPAGRATINIB) IN HCC PATIENTS AT THE PAGE MEETING

Abbisko Cayman Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**"), a subsidiary of the Company, announced that the company presented two model-based drug development advances in poster sessions at the Population Approach Group Europe Meeting ("**PAGE Meeting**"), held from June 2 to 5, 2026, in Dubrovnik, Croatia. One of the presentations highlighted a novel joint modeling framework to predict progression-free survival ("**PFS**") for ABSK-011 (irpagratinib), a highly selective FGFR4 inhibitor, in patients with advanced FGF19+ hepatocellular carcinoma ("**HCC**"). Additionally, Abbisko Therapeutics, together with an external collaborator, presented a population pharmacokinetic modeling study of ABSK-011 using Maspectra, an innovative modeling software independently developed in China, including a comparative analysis with NONMEM.

This is a voluntary announcement made by the Company. The Group cannot guarantee that ABSK 011 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, 4 June 2026

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Ji Jing as executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Ms. Chui Hoi Yam as independent non-executive directors.

Abbisko Therapeutics Presents a Novel Joint Modeling Framework for ABSK-011 (irpagratinib) in HCC patients at the PAGE Meeting

On June 4, 2026, Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**") announced that the company presented two model-based drug development advances in poster sessions at the Population Approach Group Europe Meeting ("**PAGE Meeting**"), held from June 2 to 5, 2026, in Dubrovnik, Croatia. One of the presentations highlighted a novel joint modeling framework to predict progression-free survival ("**PFS**") for ABSK-011 (irpagratinib), a highly selective FGFR4 inhibitor, in patients with advanced FGF19+ hepatocellular carcinoma ("**HCC**"). Additionally, Abbisko Therapeutics, together with an external collaborator, presented a population pharmacokinetic modeling study of ABSK-011 using Maspectra, an innovative modeling software independently developed in China, including a comparative analysis with NONMEM.

Poster Information

- Title: Predicting progression-free survival for ABSK-011 (irpagratinib) in advanced FGF19+ HCC patients via joint modeling of tumor growth dynamics
- Time: Wed, Jun 3, 2026 10:30AM-12:00PM (CEST)
- Abstract #: 12177

Poster Information

- Title: Comparison of Maspectra and NONMEM for Population Pharmacokinetic Modeling: An ABSK-011 (irpagratinib) Case Study
- Time: Wed, Jun 3, 2026 10:00AM-12:00PM (CEST)
- Abstract #: 12072

At this PAGE Meeting, Abbisko Therapeutics showcased two model-based drug development advances, highlighting the company's growing expertise in quantitative pharmacology and innovative modeling methodologies. Notably, the joint TGD-PFS modeling framework for ABSK-011 represents a significant contribution to the field, offering a more robust approach to support clinical decisions and pivotal trial design. Additionally, the comparative study of Maspectra and NONMEM demonstrates Abbisko Therapeutics' proactive engagement in the practical application of a domestically developed modeling software from China, reflecting the company's commitment to supporting homegrown technologies. These efforts underscore Abbisko's dedication to both advancing its pipelines and contributing to the evolution of model-based drug development paradigms.

Looking ahead, Abbisko Therapeutics will continue to focus on addressing unmet medical needs and accelerating the translation of innovative discoveries into clinical applications, with the goal of delivering more first-in-class and best-in-class therapies to patients worldwide.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd. is an oncology-focused biopharmaceutical company based in Shanghai that is dedicated to the discovery and development of innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich research & development and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of innovative programs focused on precision oncology and immuno-oncology.

Please visit www.abbisko.com for more information.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.